Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation

Clinical Transplantation

Volumn 21, Issue 3, 2007, Pages 417-422

  Cho, Yo Han ^a   Lim, Hyun Ae ^b   Lee, Mark Hong ^b   Kim, Inho ^c,d   Lee, Jong Seok ^d   Park, Seong Yang ^c,d   Kim, Byoung Kook ^c,d   Yoon, Sung Soo ^c,d  

^a Konkuk University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

Busulfan; Intravenous; Pharmacokinetics; Stem cell transplantation

Indexed keywords

ANTIBIOTIC AGENT; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IMMUNOGLOBULIN; METHOTREXATE; PHENYTOIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KOREA; LIVER VEIN OBSTRUCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; STOMATITIS;

ADOLESCENT; ADULT; AREA UNDER CURVE; BUSULFAN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED;

EID: 34248214199     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00664.x     Document Type: Article

References (16)

1. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994: 84: 2144.
2. Grochow LB. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993: 20: 18.
3. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997: 89: 3055.
4. Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant 2000: 6: 548.
5. Andersson BS, Kashyap A, Gian V et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 2002: 8: 145.
6. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft vs. host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729.
7. Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987: 44: 778.
8. Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr B Biomed Appl 1995: 668: 107.
9. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995: 16: 31.
10. Deeg HJ, Shulman HM, Anderson JE et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000: 95: 1188.
11. Bolinger AM, Zangwill AB, Slattery JT et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001: 28: 1013.
12. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996: 17: 225.
13. Lee JH, Choi SJ, Kim SE et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005: 84: 321.
14. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998: 92: 4568.
15. Mcdonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993: 118: 255.
16. Reiss U, Cowan M, Mcmillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002: 24: 746.